Tonix Pharmaceuticals Announces Development of TNX-601 ER, a Potential Abuse Deterrent, Extended-Release Formulation of Tianeptine Oxalate for the Treatment of Major Depressive Disorder - GlobeNewswire
Submitted by Anonymous (not verified) on Mon, 07/11/2022 - 07:00
